A. Bodurtha

1.0k total citations
23 papers, 763 citations indexed

About

A. Bodurtha is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, A. Bodurtha has authored 23 papers receiving a total of 763 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in A. Bodurtha's work include Melanoma and MAPK Pathways (5 papers), Immunotherapy and Immune Responses (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). A. Bodurtha is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), Immunotherapy and Immune Responses (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). A. Bodurtha collaborates with scholars based in Canada, United States and New Zealand. A. Bodurtha's co-authors include Noreen M. Walsh, S. T. Norvell, A. S. Macdonald, A. Guclu, Michael J. Mastrangelo, T. Ghose, Ian Quirt, Donald P. Cameron, Darwin O. Chee and H. Silver and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

A. Bodurtha

23 papers receiving 694 citations

Peers

Countries citing papers authored by A. Bodurtha

Since Specialization

Citations

This map shows the geographic impact of A. Bodurtha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Bodurtha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Bodurtha more than expected).

Fields of papers citing papers by A. Bodurtha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Bodurtha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Bodurtha. The network helps show where A. Bodurtha may publish in the future.

Co-authorship network of co-authors of A. Bodurtha

This figure shows the co-authorship network connecting the top 25 collaborators of A. Bodurtha. A scholar is included among the top collaborators of A. Bodurtha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Bodurtha. A. Bodurtha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group 2002 ·Investigational New Drugs ·Ian Quirt, A. Bodurtha, Reinhard Lohmann, James J. Rusthoven, Karl Bélanger, Vincent Young, Nancy Wainman, (unknown), Elizabeth A. Eisenhauer	35
2	Sentinel lymph-node biopsy in breast cancer. 1999 ·Europe PMC (PubMed Central) ·David R. McCready, A. Bodurtha, Noelle Davis, Sarkis Meterissian, J Robert, Walley Temple	9
3	Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. 1996 ·Journal of Clinical Oncology ·James J. Rusthoven, Ian Quirt, N. Iscoe, P. B. McCulloch, (unknown), Reinhard Lohmann, Jens‐Ulrik Stæhr Jensen, Susan Burdette-Radoux, A. Bodurtha, H. Silver, S. Verma, George Armitage, Benny Zee, Kathleen Bennett	118
4	Nova Scotia Breast Screening Program experience: use of needle core biopsy in the diagnosis of screening-detected abnormalities. 1996 ·Radiology ·Judy Caines, (unknown), Barbara Wright, G P Konok, Sian Iles, A. Bodurtha, (unknown), (unknown)	13
5	Phase II trial of 10-EDAM in advanced soft tissue sarcoma 1994 ·Annals of Oncology ·Margaret A. Knowling, V. Bramwell, E. Eisenhauer, (unknown), A. Bodurtha, Ian Quirt	7
6	A phase II study of weekly Edatrexate (10-EDAM) in metastatic melanoma 1993 ·Annals of Oncology ·Sunil Verma, Ian Quirt, E. Eisenhauer, N. Iscoe, (unknown), A. Bodurtha, J. A. Davidson	7
7	Isolation of Klebsiella Pneumoniae from an Hepatic Inflammatory Pseudotumour 1992 ·Canadian Journal of Gastroenterology and Hepatology ·(unknown), John Morris, A. Bodurtha	10
8	Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. 1991 ·Journal of Clinical Oncology ·Ian Quirt, W Shelley, Joe Pater, A. Bodurtha, (unknown), T. A. McPherson, Alexander Paterson, Ross L. Prentice, H. Silver, Andrew R. Willan	58
9	Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study 1990 ·Investigational New Drugs ·Neill Iscoe, Elizabeth A. Eisenhauer, A. Bodurtha	5
10	Auerbach's myenteric plexus. A possible site of origin for gastrointestinal stromal tumors in von Recklinghausen's neurofibromatosis. 1990 ·PubMed ·Noreen M. Walsh, A. Bodurtha	52
11	Prognostic factors in colorectal carcinoma of young adults. 1988 ·Canadian Journal of Surgery ·(unknown), Derrick J. Pounder, (unknown), A. Bodurtha, (unknown)	47
12	Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. 1985 ·PubMed ·W Shelley, Ian Quirt, A. Bodurtha, N. Iscoe, James Russell, Alexander Paterson, Duncan Young	3
13	A phase II study of spirogermanium in patients with metastatic malignant melanoma 1985 ·Investigational New Drugs ·Elizabeth A. Eisenhauer, Ian G. Kerr, A. Bodurtha, Neill Iscoe, Peter McCulloch, Kathleen I. Pritchard, Ian Quirt	5
14	A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma 1977 ·Cancer ·(unknown), A. Bodurtha, Michael J. Mastrangelo, Robert E. Bellet	32
15	ANTIBODIES AS CARRIERS OF RADIONUCLIDES AND CYTOTOXIC DRUGS IN THE TREATMENT AND DIAGNOSIS OF CANCER 1976 ·Annals of the New York Academy of Sciences ·T. K. Ghose, J. Tai, A. Guclu, S. T. Norvell, A. Bodurtha, (unknown), A. S. Macdonald	16
16	A clinical, histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission 1976 ·Cancer ·A. Bodurtha, Jane Berkelhammer, (unknown), (unknown), Michael J. Mastrangelo	37
17	Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors 1975 ·International Journal of Cancer ·Jane Berkelhammer, Michael J. Mastrangelo, (unknown), A. Bodurtha, Richmond T. Prehn	20
18	Hepatic Granulomas and Other Hepatic Lesions Associated with BCG Immunotherapy for Cancer 1974 ·American Journal of Clinical Pathology ·A. Bodurtha, (unknown), (unknown), (unknown), Michael J. Mastrangelo	26
19	Facilitation and inhibition of B16 melanoma by BCG in vivo and by lymphoid cells from BCG‐treated mice in vitro 1974 ·International Journal of Cancer ·Darwin O. Chee, A. Bodurtha	37
20	Immunochemotherapy of Cancer with Chlorambucil-carrying Antibody 1972 ·BMJ ·T. Ghose, S. T. Norvell, A. Guclu, Donald P. Cameron, A. Bodurtha, A. S. Macdonald	114

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact